Matinas BioPharma Holdings, Inc.
MTNB
Rank in Stocks
#33458
Matinas BioPharma Holdings, Inc. is a biopharmaceutical firm in the clinical... Matinas BioPharma Holdings, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying and advancing a range of potential therapeutic products. The company's innovative Lipid Nanocrystal (LNC) platform technology underpins its product development efforts. This sophisticated LNC delivery system leverages lipid nano-crystals to transport a diverse array of therapeutic agents, including small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its primary experimental drug, LYPDISO, is a proprietary, prescription-grade omega-3 free fatty acid compound engineered to address cardiovascular and metabolic disorders. Matinas BioPharma is also advancing MAT2203, an orally administered version of amphotericin B. This candidate is currently in Phase II clinical trials, where it is being evaluated for its ability to prevent invasive fungal infections in patients undergoing immunosuppressive treatment. Furthermore, MAT2501, an oral formulation of the broad-spectrum aminoglycoside antibiotic amikacin, has successfully completed Phase I clinical trials. Its aim is to combat a spectrum of multidrug-resistant bacterial infections, such as non-tuberculous mycobacterium, multidrug-resistant gram-negative, and intracellular bacterial pathogens. The company actively engages in collaborations, including a research partnership with the National Institute of Allergy and Infectious Diseases (NIAID) to further the development of Gilead's antiviral drug, remdesivir. Additionally, it has a feasibility collaboration with Genentech, Inc. focused on creating new oral drug formulations. Established in 2013, Matinas BioPharma maintains its corporate headquarters in Bedminster, New Jersey.
Share Price
$1.24
Last synced: 2026-11-09
Market Cap
$529.58K
Change (1 day)
4.20%
Change (1 year)
3.33%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Matinas BioPharma Holdings, Inc. (MTNB)
Category
Healthcare
Operating Margin for Matinas BioPharma Holdings, Inc. (MTNB)
Operating Margin as of November 2026 TTM: 0.00%
According to Matinas BioPharma Holdings, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Matinas BioPharma Holdings, Inc. from 2012 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | -100.00% |
| 2023 | -2,168.43% | 181.13% |
| 2022 | -771.33% | -98.97% |
| 2021 | -74,954.55% | 390.27% |
| 2020 | -15,288.38% | -27.43% |
| 2019 | -21,067.38% | 72.25% |
| 2018 | -12,230.94% | 10.94% |
| 2017 | -11,024.61% | 0.00% |
| 2016 | 0.00% | -100.00% |
| 2015 | -5,096.04% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Matinas BioPharma Holdings, Inc.'s operating margin
What was Matinas BioPharma Holdings, Inc.'s operating margin in 2025?
In 2025, Matinas BioPharma Holdings, Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has Matinas BioPharma Holdings, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Matinas BioPharma Holdings, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2021 (-74,954.55%).
How does Matinas BioPharma Holdings, Inc.'s operating margin compare with similar companies?
Matinas BioPharma Holdings, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.